EHA 2024: Bispecific Antibodies and New Advances in Myeloma Treatment with Dr. Ola Landgren

Myeloma specialist and researcher Dr. Ola Landgren shares important insights about bispecific antibody therapy and quadruplet therapy at the European Hematology Association (EHA) in Madrid. 

At EHA, Dr. Landgren participated in the international expert discussion on bispecific antibodies. He discussed key considerations when prescribing bispecific antibodies, provided a deep dive into data for bispecifics.. 

Key Considerations for T-cell Myeloma Treatment

Managing T-cell directing therapies for relapsed-refractory multiple myeloma is a clinical challenge for doctors. 

Key considerations for managing these therapies include: 

• Therapy goals 
• Previous lines of therapy 
• Myeloma genetics and profile 
• Patient characteristics 

Deep Dive Data of Bispecific Antibody Therapy for Myeloma

He shared the findings after a deep dive into diverse studies with teclistamab, talquetamab, and elranatamab. These studies showed that even in patients with extramedullary disease or a large plasma cell percentage, all age groups and frailty scales could receive these treatments because of the great response rates (over 60%), very high rates of minimal residual disease (MRD) negativity, and long progression-free survival. Overall, this analysis showed the positive effects of bispecific therapies in patients with relapsed and refractory multiple myeloma. 

Four-Drug Therapies for Newly Diagnosed Myeloma Patients

Dr. Landgren shed light on his ASCO 2024 presentation on quadruple therapy for newly diagnosed myeloma patients, in which he shared that quadruplet therapies, or using four anti-myeloma drugs at the same time, show higher rates of MRD negativity and longer progression-free survival compared to triplet therapies, regardless of age and transplant eligibility. Based on the data found in the study, a four-drug regimen (quadruple therapy) can be established as a new standard of care for newly diagnosed patients.  

Dr. Landgren's insights at EHA highlight the promise of bispecific antibodies for relapsed-refractory myeloma. These therapies show high response rates and long progression-free survival, and quadruple therapy for new patients may become the new standard of care.

Unlock Personal Insights Into Your Diagnosis for Free with HealthTree Cure Hub, the platform that powers life-saving research!

You can contribute to research by securely connecting your electronic health records. HealthTree Cure Hub allows you to discover treatment options, find a specialist, keep track of your disease, and so much more! Sign up for a free patient account today to get started.

CREATE MY FREE ACCOUNT

Sources: 

• How to Make the Most out of a Rapidly Evolving Treatment Landscape: Bispecific Antibodies in Relapsed Refractory Multiple Myeloma (RRMM)
• The More the Better? Quadruplets in Newly Diagnosed Multiple Myeloma